{"filing":{"accession_number":"0001759425-26-000049","cik":"0001759425","ticker":"MIRM","company_name":"Mirum Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-25","primary_document":"mirm-20260925.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1759425/000175942526000049/mirm-20260925.htm"},"events":[{"id":35317,"run_id":32525,"accession_number":"0001759425-26-000049","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This Item 8.01 discloses two major operational milestones: (1) FDA approval of Atebrioz (zilurgisertib) for FOP on September 25, 2026, with commercial availability expected in October 2026, and (2) announcement on September 28, 2026 that brelovitug met its primary endpoint in the Phase 3 AZURE-1 study for chronic hepatitis delta, with BLA submission expected in H1 2027 and commercial launch in Q4 2027. These are material regulatory and clinical achievements that advance the company's pipeline and revenue prospects (estimated \u003e$200M for Atebrioz and \u003e$1B for brelovitug annually), but they do not fit neatly into the specific event categories (not earnings, not M\u0026A, not impairment, not litigation). The disclosure centers on product development milestones and regulatory progress rather than a single discrete event type, making operational_other the most appropriate classification.","company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39331,"accession_number":"0001759425-26-000049","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This Item 8.01 discloses two major operational milestones: (1) FDA approval of Atebrioz (zilurgisertib) for FOP on September 25, 2026, with commercial availability expected in October 2026, and (2) announcement on September 28, 2026 that brelovitug met its primary endpoint in the Phase 3 AZURE-1 study for chronic hepatitis delta, with BLA submission expected in H1 2027 and commercial launch in Q4 2027. These are material regulatory and clinical achievements that advance the company's pipeline and revenue prospects (estimated \u003e$200M for Atebrioz and \u003e$1B for brelovitug annually), but they do not fit neatly into the specific event categories (not earnings, not M\u0026A, not impairment, not litigation). The disclosure centers on product development milestones and regulatory progress rather than a single discrete event type, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:08:07.158294+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39331,"accession_number":"0001759425-26-000049","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This Item 8.01 discloses two major operational milestones: (1) FDA approval of Atebrioz (zilurgisertib) for FOP on September 25, 2026, with commercial availability expected in October 2026, and (2) announcement on September 28, 2026 that brelovitug met its primary endpoint in the Phase 3 AZURE-1 study for chronic hepatitis delta, with BLA submission expected in H1 2027 and commercial launch in Q4 2027. These are material regulatory and clinical achievements that advance the company's pipeline and revenue prospects (estimated \u003e$200M for Atebrioz and \u003e$1B for brelovitug annually), but they do not fit neatly into the specific event categories (not earnings, not M\u0026A, not impairment, not litigation). The disclosure centers on product development milestones and regulatory progress rather than a single discrete event type, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:08:07.158294+00:00","company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","filing_date":"2026-09-28"}]}